JP2019006815A5 - - Google Patents

Download PDF

Info

Publication number
JP2019006815A5
JP2019006815A5 JP2018173770A JP2018173770A JP2019006815A5 JP 2019006815 A5 JP2019006815 A5 JP 2019006815A5 JP 2018173770 A JP2018173770 A JP 2018173770A JP 2018173770 A JP2018173770 A JP 2018173770A JP 2019006815 A5 JP2019006815 A5 JP 2019006815A5
Authority
JP
Japan
Prior art keywords
lipid
mole
peg
chol
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018173770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019006815A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019006815A publication Critical patent/JP2019006815A/ja
Publication of JP2019006815A5 publication Critical patent/JP2019006815A5/ja
Pending legal-status Critical Current

Links

JP2018173770A 2013-03-13 2018-09-18 修飾されたドセタキセルリポソーム製剤 Pending JP2019006815A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779902P 2013-03-13 2013-03-13
US61/779,902 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017177620A Division JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤

Publications (2)

Publication Number Publication Date
JP2019006815A JP2019006815A (ja) 2019-01-17
JP2019006815A5 true JP2019006815A5 (enExample) 2019-07-25

Family

ID=50686145

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502155A Expired - Fee Related JP6294456B2 (ja) 2013-03-13 2014-03-13 修飾されたドセタキセルリポソーム製剤
JP2017177620A Pending JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤
JP2018173770A Pending JP2019006815A (ja) 2013-03-13 2018-09-18 修飾されたドセタキセルリポソーム製剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016502155A Expired - Fee Related JP6294456B2 (ja) 2013-03-13 2014-03-13 修飾されたドセタキセルリポソーム製剤
JP2017177620A Pending JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤

Country Status (8)

Country Link
US (1) US20140271822A1 (enExample)
EP (1) EP2968145A1 (enExample)
JP (3) JP6294456B2 (enExample)
CN (1) CN105188675A (enExample)
BR (1) BR112015022819A8 (enExample)
CA (1) CA2903255C (enExample)
MX (1) MX2015012201A (enExample)
WO (1) WO2014160392A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160392A1 (en) * 2013-03-13 2014-10-02 Mallinckrodt Llc Modified docetaxel liposome formulations
CN104622810B (zh) * 2015-02-15 2018-06-08 中国药科大学 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
US10918599B2 (en) 2015-04-02 2021-02-16 The Research Foundation For The State University Of New York Serum-stable compositions and methods for light-triggered release of materials
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
MY198105A (en) * 2016-01-07 2023-08-02 Univ Western Health Sciences Formulations for treating bladder cancer
EP3429631A1 (en) * 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
JP2019512477A (ja) * 2016-03-16 2019-05-16 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体a2(epha2)のナノリポソーム標的化及び関連する診断
CN109310782A (zh) * 2016-03-16 2019-02-05 梅里麦克制药股份有限公司 肝配蛋白受体A2(EphA2)靶向性的多西他赛生成纳米脂质体组合物
IL264842B (en) * 2016-08-18 2022-08-01 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
US20210290537A1 (en) * 2016-12-08 2021-09-23 Mallinckrodt Llc Liposomal elinafide formulations and uses thereof
EP3648758A4 (en) 2017-07-07 2021-04-28 Drexel University TENSION-ACTIVATED THERAPEUTIC, DIAGNOSTIC AND / OR THERANOSTIC CONSTRUCTIONS
CN110496103B (zh) * 2018-05-18 2022-05-10 上海维洱生物医药科技有限公司 一种多西他赛棕榈酸酯脂质体及其制备方法
WO2020056102A1 (en) * 2018-09-13 2020-03-19 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
JP7477844B2 (ja) * 2018-10-17 2024-05-02 タイワン リポソーム カンパニー リミテッド 免疫調節剤を含む徐放性医薬組成物およびその使用
JP2022544197A (ja) * 2019-08-09 2022-10-17 テソリックス ファーマ, エルエルシー プロリポソームウンデカン酸テストステロン製剤
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114588279B (zh) * 2022-03-31 2023-10-20 重庆医科大学附属第二医院 一种多功能纳米分子探针及其制备方法和其作为视网膜母细胞瘤诊疗制剂的应用
TW202527957A (zh) * 2023-12-13 2025-07-16 大陸商上海艾力斯醫藥科技股份有限公司 一種含氮雜環化合物的脂質體及其應用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
EP1809246B1 (en) * 2004-10-08 2008-07-16 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
EP1871424A2 (en) * 2005-04-22 2008-01-02 Alza Corporation Immunoliposome composition for targeting to a her2 cell receptor
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
KR101919093B1 (ko) * 2008-05-23 2018-11-16 더 유니버시티 오브 브리티쉬 콜롬비아 리포좀 나노입자에 사용하기 위한 변형된 약물
CN102038641B (zh) * 2009-10-26 2013-04-17 石药集团中奇制药技术(石家庄)有限公司 一种外层经亲水聚合物修饰的脂质体药物的制备方法
US20120231066A1 (en) * 2011-01-24 2012-09-13 Henry John Smith Multi-drug liposomes to treat tumors
CN103338747A (zh) * 2011-01-28 2013-10-02 皇家飞利浦电子股份有限公司 用于局部释放亲水性前药的载体
CN102188713A (zh) * 2011-05-09 2011-09-21 中山大学 一种肝靶向药物组合物及其制备方法
WO2014160392A1 (en) * 2013-03-13 2014-10-02 Mallinckrodt Llc Modified docetaxel liposome formulations

Similar Documents

Publication Publication Date Title
CN101043875B (zh) 糖皮质激素和糖皮质激素衍生物的脂质体组合物
JP2021522163A5 (enExample)
JP2020510072A5 (enExample)
CN101991538B (zh) 一种含tpgs的脂质体组合物及其应用
PT2508170E (pt) Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
CA2739822A1 (en) Liposomal systems comprising sphingomyelin
WO2016027264A1 (en) Targeted liposomes encapsulating iron complexes and their uses
WO2005117878A1 (ja) イリノテカン製剤
JP7770367B2 (ja) 徐放性麻酔剤組成物およびその調製方法
JP2016513651A5 (enExample)
US20210213051A1 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
CN105188675A (zh) 经修饰多西他赛脂质体制剂
JP2018527335A5 (enExample)
JP6230538B2 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
TWI767133B (zh) 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途
JP4833836B2 (ja) リポソーム製剤
JP2024526791A (ja) リポソーム製剤の調製方法
JP2022500398A5 (enExample)
WO2006027785A1 (en) Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions
AU2016233143B2 (en) Methods for the treatment of bladder cancer
JP2024526800A (ja) Bcl阻害剤のリポソーム製剤
HK40043569A (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases